Market Overview

Research and Markets: Cutaneous Lupus Erythematosus - Pipeline Review, H2 2012

Share:
DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/d76zlc/cutaneous_lupus) has announced the addition of Global Markets Direct's new report "Cutaneous Lupus Erythematosus - Pipeline Review, H2 2012" to their offering.

'Cutaneous Lupus Erythematosus - Pipeline Review, H2 2012', provides an overview of the Cutaneous Lupus Erythematosus therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous Lupus Erythematosus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cutaneous Lupus Erythematosus.

Scope

- A snapshot of the global therapeutic scenario for Cutaneous Lupus Erythematosus.

- A review of the Cutaneous Lupus Erythematosus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Cutaneous Lupus Erythematosus pipeline on the basis of route of administration and molecule type.

- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cutaneous Lupus Erythematosus.

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Cutaneous Lupus Erythematosus pipeline depth and focus of Cutaneous Lupus Erythematosus therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit http://www.researchandmarkets.com/research/d76zlc/cutaneous_lupus

Source: Global Markets Direct

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals




View Comments and Join the Discussion!